EUVIMEDEUVIMED entdecken
Crossref

Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer

Joyeeta Roy iD, Rima Mouawad iD, Armita Kyani, Maha Hanafi iD, Yibin Xu iD, Bo Wen, Duxin Sun iD, Nouri Neamati iD

Journal of Medicinal Chemistry · 24.04.2025 · 68 (8) · 8400-8428

DOI: 10.1021/acs.jmedchem.4c03159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.03.2025. Verfasst von Joyeeta Roy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, North Campus Research Complex, 1600 Huron Parkwa…. Hauptthemen laut MEDLINE: Copper, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS mutations are a hallmark of pancreatic ductal adenocarcinoma (PDAC), occurring in over 90% of tumors. Tumors with these mutations are highly dependent on copper, making the targeting of copper homeostasis an attractive strategy for treating PDAC due to the higher copper requirement of cancer cells compared to normal cells. Herein, we present the discovery, lead optimization, and structure-activity relationship study of a series of novel quinolyl pyrazinamides for the treatment PDAC. These compounds induce cell death through copper-mediated apoptosis and necroptosis. Our optimized compounds, 39 and 52, are potent, water-soluble and metabolically stable. Compound 52 exhibits 55% oral bioavailability and demonstrates significant in vivo efficacy without obvious toxicity in syngeneic models of PDAC. Additionally, compound 52 showed significant synergy with celecoxib, a selective COX2 inhibitor, both in vitro and in vivo. Our data suggest that compound 52 is a promising candidate for further development in KRAS-mutated cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CopperPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Antineoplastic AgentsCyclooxygenase 2Carcinoma, Pancreatic DuctalCyclooxygenase 2 InhibitorsHumansAnimalsStructure-Activity RelationshipMiceCell Line, TumorApoptosis

Substanzen

CopperProto-Oncogene Proteins p21(ras)Antineoplastic AgentsKRAS protein, humanCyclooxygenase 2Cyclooxygenase 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, North Campus Research Complex, 1600 Huron Parkway, Ann Arbor, Michigan 48109, United States.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, North Campus Research Complex, 1600 Huron Parkway, Ann Arbor, Michigan 48109, United States.

ORCID-Profile: Joyeeta Roy, Rima Mouawad, Maha Hanafi, Yibin Xu, Duxin Sun, Nouri Neamati

Förderung

  • National Cancer Institute

Zitieren

APA

Roy, J., Mouawad, R., Kyani, A., Hanafi, M., Xu, Y., Wen, B., Sun, D., & Neamati, N. (2025). Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. Journal of Medicinal Chemistry, 68(8), 8400-8428. https://doi.org/10.1021/acs.jmedchem.4c03159

Vancouver

Roy J, Mouawad R, Kyani A, Hanafi M, Xu Y, Wen B, et al. Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. Journal of Medicinal Chemistry. 2025;68(8):8400-8428. doi:10.1021/acs.jmedchem.4c03159

BibTeX
@article{Roy2025,
  author = {Roy, Joyeeta and Mouawad, Rima and Kyani, Armita and Hanafi, Maha and Xu, Yibin and Wen, Bo and Sun, Duxin and Neamati, Nouri},
  title = {Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {8},
  pages = {8400--8428},
  doi = {10.1021/acs.jmedchem.4c03159}
}
Kostenlos starten →